Table of Contents
Study 310: Univariate Logistic Regression - RAPA Group
Study 212 Enrolled 19.1% Black Patients
Study 212: All 13 Eligible Black Patients Successfully Eliminated CsA
Study 212: Similar Rates of Acute Rejection at Months 2 and 12
Study 212: Significantly Higher Calculated GFR at Month12 in the RAPA Group, Black Patients
Study 212: Numerically Lower BP in RAPA Group - Black Patients
Study 212: Patient & Graft Survival (%) By Ethnic Origin: Month 12
Study 310: No (S.D.) Difference in CADI Score at 1 Year
Renal Function (Observed Mean) Patients With Biopsy Vs No Biopsy
Study 310: Nonrandomized Patients (Ninety-Five Discontinued Prior to Randomized at Month 3)
Study 310 Adverse Events Leading to Discontinuation Prior to Randomization at Month 3
Study 310: 70% of Patients With Acute Rejection Prerandomization – Eventually Randomized
Study 310 Nonrandomized Patients: Other causes of discontinuation
Study 310: No Rejections in RAPA Group: 12-24 Months
Renal Function at 12 Months Predicts Long Term Graft Survival
Study 310: Predicted Long Term Graft Survival Better with RAPA
Slope of 1000/Creatinine All Data Between 6 and 24 Months
Slope of 1000/Creatinine All Data Between 12 and 24 Months
Study 310 Histologic Grade of First Biopsy Confirmed-Acute Rejection by Grade: 12 Months
Study 310: Decreasing Doses of CsA in RAPA Group With Time to First Rejection
Study 310 Thirty-One Patients Discontinued at the 3 Month Visit (Days 75-140)
Study 310: Lower Mean Serum Potassium (mmol/L) Levels Following Cyclosporine Withdrawal
Study 310: Mean Sirolimus Troughs/Levels and Doses Through 24 Months
Study 310: Lower Serum Creatinine Following CsA Elimination - Completers Through 24 Months
Study 310: PK-PD Analysis Confirms Flexibility of the RAPAMUNE - CsA Combination
Studies 207 Plus 210: Lipid Levels vs RAPA Trough Concentrations
Studies 207 Plus 210 SGPT Values
Study 207 Concentration - Effect
|